Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Last Trading Update
Revenue recognised for 2024 is expected to treble compared to 2023 with the growth of distributor sales, and with the planned launches of the Portrait PD-L1 test (services), see separate announcement today, the Portrait+ antibody staining kit (products), and the Parsortix BiDetectTM DNA solutions combining ctDNA and CTC-DNA analysis (products and services) all contributing to the Company's sales growth ambitions.
Business update - Streamlining services business extends cash runway
With the expected growth in molecular solutions requiring investment and considering ongoing adverse market conditions, we have made the decision to streamline our Services operations by closing the US clinical laboratory and focusing on a single UK-based centre of excellence. We have developed solutions for sample stability so that the physical location of the laboratory does not limit its capability to service customers across different geographies. The streamlining will enable us to focus our investment in multiple molecular platforms for different applications in a single location without duplicating these significant costs.
ANGLE Founder and Chief Executive, Andrew Newland, commented:
"The build-up of revenues has been slower than hoped but is moving in the right direction and the Company expects strong revenue growth year-on-year. The cost savings from the streamlining of our clinical services business will now extend the forecast cash runway into Q2 2025 and we look forward to progressing the planned launches of new products and services to drive widespread adoption of the Company's Parsortix system to support precision medicine in cancer."
Berenberg Bank reaffirmed their buy rating on shares of ANGLE (LON:AGL – Free Report) in a research report released on Wednesday morning, Marketbeat Ratings reports. The brokerage currently has a GBX 70 ($0.86) target price on the stock
There is a seller and they have been offloading in batches of 50000 and 25000. We will soon find out.
European Patent Office has granted a European Patent for its innovative CellKeep™ slide. A formal communication has also been received from the United States Patent and Trademark Office indicating that grant of the equivalent US patent application is imminent. News due soon
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix® system and associated consumables. The clinical services business is offered through ANGLE's GCP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma.
Over 90 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com
There is also a distressed seller offloading for the past few days . Hopefully should be TR1 soon. That is what is also holding this back
Since the RNS there has been 480K buy and also other big buys. Mms have been filling order.
Https://www.lse.co.uk/ShareBrokerTips.html?shareprice=AGL&share=Angle
Broker Rating 70p